Equities

Cyclopharm Ltd

Cyclopharm Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)1.37
  • Today's Change0.015 / 1.11%
  • Shares traded4.05k
  • 1 Year change-33.17%
  • Beta0.6499
Data delayed at least 20 minutes, as of Nov 18 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The one analyst offering a 12 month price target expects Cyclopharm Limited share price to rise to 2.70 in the next year from the last price of 1.37.
High97.1%2.70
Med97.1%2.70
Low97.1%2.70

Dividends

In 2023, Cyclopharm Ltd reported a dividend of 0.01 AUD, which represents a 50.00% decrease from last year. The analyst covering the company expects dividends of 0.01 AUD for the upcoming fiscal year, an increase of 100.00%.
Div growth (TTM)-50.00%
More ▼

Earnings history & estimates in AUD

Cyclopharm Limited reported annual 2023 losses of -0.051 per share on Feb 27, 2024.
Average growth rate+10.17%
More ▼

Revenue history & estimates in AUD

Cyclopharm Limited had revenues for the full year 2023 of 26.34m. Last year the company did not report any revenues.
Average growth rate+19.67%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.